Webcode 25092003
Florian Innig
Alliance of Chronic Rare Diseases (ACHSE), Berlin
Florian Innig has long been associated with the topic of dwarfism and works for BKMF e.V., the German association for short statured people and their families. In recent years, in addition to his work for the association, he has also been involved in the evaluation of medicinal products. Since 2019, Florian is a permanent patient representative in the Federal Joint Committee's Pharmaceuticals Sub-Committee. Medicinal products are also his focus in the Board of ACHSE e.V., the German umbrella organization for rare diseases. He is in the DITA as well as the HTA task force of EURORDIS.
Veronica Lopez Gousset
VLG Advocacy and Health Systems Consulting, Boston, USA
Independent consultant; Veronica Lopez Gousset, MPH has more than 8 years of experience ensuring patients’ voices are represented in healthcare decision-making. Since 2020, has been working to support the characterization of the impact of patient involvement in HTA. She has presented, trained, and published on this topic and co-leads a project focused on identifying good practices in this area under Health Technology Assessment International (HTAi)’s Patient and Citizen Involvement Interest Group (PCIG). She is also a Steering Committee member of HTAi’s Rare Disease Interest Group and co-leads the group’s project on knowledge dissemination.
Dr. Andreas L.G. Reimann, MBA
admedicum Business for Patients GmbH & Co KG, Cologne
Founder and Managing Director
More information please click here.
Prof Sophie Staniszewska
University of Warwick, GREAT BRITAIN
Patient and Public Involvement and Experiences of Care, Honorary Professor, University Hospitals Coventry and Warwickshire Co-Editor in Chief, Research Involvement and Engagement, Co-Director, Warwick Research in Nursing
Victoria Thomas
Victoria Thomas Consultancy, UK
Victoria Thomas has worked for many years in the regulatory sector focusing on involvement in health technology assessment (HTA) and guideline development, and across a range of voluntary and community sector organisations. Her experience includes working directly with people with lived experience, and with the organisations that support them.
Jo Wallis
kintiga, UK
Vice President, Early Strategic Advice and Market Access UK/IRE
10/09/2025
10/09/2025
9:00 am - 5:00 pm seminar
You may dial in 30 minutes in advance
online
online
Veranstaltung - 1,290 € zzgl. MwSt.
The fee includes high-quality course material for download, a certificate of participation, access to our Learning Space and technical support, including a test meeting.
Veranstaltung - 1,290 € zzgl. MwSt.
The fee includes high-quality course material for download, a certificate of participation, access to our Learning Space and technical support, including a test meeting.
Dr. Henriette Wolf-Klein
Head of Department
+49 6221 500-680
h.wolf-klein@forum-institut.de
This course offers a deep dive into patient involvement in HTA processes across Europe, with a focus on the UK and Germany - learn practical approaches, regulatory insights, and how to engage meaningfully with patient organisations.
This course offers comprehensive insights into the evolving role of patients and patient advocates in HTA processes across Europe. You will explore how and when patients are involved, drawing on both national experiences and European regulatory frameworks.
The agenda includes perspectives on NICE, the AMNOG process, the new EU HTA regulation, and methodological aspects such as patient-reported outcomes and further outcome measures. You will gain a deep understanding of the value and impact of patient contributions to HTA, supported by real-world examples and best practices.
09:00 Introduction and participants expectations
09:15
Veronica Lopez Gousset
10:00
Dr. Andreas L.G. Reimann, MBA
10:45 Coffee break
11:00
Jo Wallis
11:45 Short break
11:55
Florian Innig
12:40 Lunch break
13:45
Victoria Thomas
14:30 Short break
14:40
Prof Sophie Staniszewska
15:25 Coffee break
15:45
Dr. Andreas L.G. Reimann, MBA
16:30 Final discussion
17:00 Seminar end
of 5 stars of all ratings from 2024
of 5 stars on Trustpilot = good
CCDS, Lieferkettensorgfaltspflichtengesetz u.v.m. - welche Berichte müssen Sie bis wann und wie verfassen? Hier erfahren...
Sie benötigen als Einsteiger*in in der Pharma-Branche ein solides Grundlagenwissen über das deutsche Gesundheitssystem? ...
Dieses Seminar adressiert Arzneimittelpreise im Fokus der Erstattungsbetragsverhandlung bei der frühen Nutzenbewertung.
Im Rahmen des Seminars erfahren Mitarbeiter*innen von Krankenkassen und pharmazeutischen Unternehmen wie die GKV "tickt"...
Dieser Workshop macht Sie fit für die G-BA Anhörung und vermittelt statistisches Know-how zur frühen Nutzenbewertung - ...
